PureTech begins trial of potential ‘Long COVID’ drug as cases mountAs the pandemic drags on there are increasing concerns about “Long COVID” – where symptoms persist long after Share XPureTech begins trial of potential ‘Long COVID’ drug as cases mounthttps://pharmaphorum.com/news/puretech-begins-trial-of-potential-long-covid-drug-as-cases-mount/
Akili presents new real-world data from therapeutic ADHD video gameAkili has new data from its childhood hyperactivity therapeutic video game EndeavorRx, as the company builds a case Share XAkili presents new real-world data from therapeutic ADHD video gamehttps://pharmaphorum.com/news/akili-presents-new-real-world-data-from-therapeutic-adhd-video-game/
PureTech’s Vedanta Biosciences gets federal funding for C. Diff. microbiome therapyUS biotech Vedanta Biosciences has been awarded up to $76.9 million to develop VE303 for high-risk Clostridioides difficile (C. Share XPureTech’s Vedanta Biosciences gets federal funding for C. Diff. microbiome therapyhttps://pharmaphorum.com/news/puretechs-vedanta-biosciences-gets-federal-funding-for-c-diff-microbiome-therapy/
Akili’s ADHD digital therapy approved in EuropeThe European Medicines Agency has approved Akili’s ground-breaking digital therapy for attention deficit hyperactivity disorder (ADHD), which uses a video Share XAkili’s ADHD digital therapy approved in Europehttps://pharmaphorum.com/news/akilis-adhd-digital-therapy-approved-in-europe/
PureTech unit Follica cues up phase 3 programme for male hair lossPureTech has said one of the companies it has founded – Follica – is preparing to start registration Share XPureTech unit Follica cues up phase 3 programme for male hair losshttps://pharmaphorum.com/news/puretech-unit-follica-cues-up-phase-3-programme-for-male-hair-loss/
Coronavirus news roundup – 29/05/2020A series of vaccines and drugs are being fast-tracked through the big pharma pipeline as part of a Share XCoronavirus news roundup – 29/05/2020https://pharmaphorum.com/views-and-analysis/coronavirus-news-roundup-29-05-2020/
FDA approves PureTech’s obesity device PlenityThe FDA has approved PureTech Health’s ‘space occupying’ device Plenity as a new prescription treatment for obesity, setting Share XFDA approves PureTech’s obesity device Plenityhttps://pharmaphorum.com/news/fda-approves-puretech-obesity-plenity/
PureTech’s Vedanta raises $27m for microbiome researchUS-based Vedanta Biosciences has raised $27 million in a Series C financing to investigate microbiome-derived therapies for several Share XPureTech’s Vedanta raises $27m for microbiome researchhttps://pharmaphorum.com/news/puretechs-vedanta-raises-27m-for-microbiome-research/
PureTech signs potential $1bn exosome deal with RocheUS biotech PureTech Health has signed a potential billion-dollar deal with Roche based around its exosome technology that Share XPureTech signs potential $1bn exosome deal with Rochehttps://pharmaphorum.com/news/puretech-signs-potential-1bn-exosome-deal-with-roche/
